 CAMBRIDGE, Mass., Sept. 19, 2022 GLOBE NEWSWIRE -- Rubius Therapeutics, Inc. Nasdaq: RUBY, a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell TherapeuticsTM for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 11:15am EDT. 